MS affects more than 1.2 million people worldwide, including 600,000 people in Europe. Spasticity is one of the most common and most disabling symptoms of MS, affecting up to 84% of patients.
It is widely recognised that currently available treatments are inadequate. Sativex has been developed as a treatment for the relief of symptoms in patients with moderate to severe spasticity that have not been adequately treated with currently used therapies. It is able to relieve spasticity, reduce spasms, improve sleep and improve function.
Please find patient information regarding Sativex and MS spasticity below: